Copy to clipboard 
Oxford Performance Materials (OPM) entered into an exclusive distribution partnership with Sovereign Medical. This exclusive collaboration will expand the reach of OPM’s 3D-printed PEKK OsteoFab-Rx personalized implant product line across the United Kingdom for lower & upper extremity and trauma applications, as well as oncology.
Like the 3DP OsteoFab technology for patient-matched CMF and standard-sized spinal implants, OsteoFab-Rx devices provide the following key benefits: metal-free & bone-like mechanics, biocompatability, inherent bacteriostatic properties, osseointegration and modifiability in the O.R. Adoption of the OsteoFab-Rx line in the U.S. has been swift, with case volume increasing four-fold in 2024.
Under this new agreement, Sovereign Medical will leverage its regulatory expertise and established relationships with U.K. medical centers to facilitate the import and distribution of OsteoFab-Rx products throughout the United Kingdom.
“We are thrilled to partner with Sovereign Medical, a company that shares our commitment to innovation and excellence in healthcare,” said Scott DeFelice, CEO of Oxford Performance Materials. “This collaboration will enable us to bring our advanced OsteoFab®-Rx products to new markets, providing patients with state-of-the-art personalized medical solutions.”
David King, CEO of Sovereign Medical, added, “We are excited to work with OPM and introduce their groundbreaking products to the UK. Our team is dedicated to ensuring that these innovative solutions reach the hospitals and patients who need them most.”
Source: Oxford Performance Materials, Inc.
